Wells Fargo & Company Raises GoodRx (NASDAQ:GDRX) Price Target to $5.00

GoodRx (NASDAQ:GDRX) had its price objective hoisted by stock analysts at Wells Fargo & Company from $3.50 to $5.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 33.33% from the stock’s current price.

Several other research firms have also issued reports on GDRX. Weiss Ratings lowered shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, July 23rd. Citigroup restated a “buy” rating on shares of GoodRx in a research note on Thursday, July 23rd. TD Cowen raised their target price on GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a report on Monday, May 11th. Leerink Partners set a $5.00 target price on GoodRx in a report on Thursday. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $4.00 price target on shares of GoodRx in a research note on Friday. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.15.

GoodRx Stock Up 0.8%

GDRX opened at $3.75 on Friday. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.47 and a current ratio of 1.47. The company has a market capitalization of $1.28 billion, a P/E ratio of 93.90, a P/E/G ratio of 1.51 and a beta of 1.60. The stock has a fifty day moving average of $2.93 and a 200-day moving average of $2.54.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. GoodRx had a return on equity of 7.32% and a net margin of 2.07%.The business had revenue of $200.41 million during the quarter, compared to analysts’ expectations of $194.56 million. During the same period in the previous year, the company posted $0.09 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. On average, equities analysts expect that GoodRx will post 0.17 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Essential Partners LLC increased its stake in shares of GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after buying an additional 11,295 shares during the period. Meridian Wealth Management LLC bought a new position in shares of GoodRx during the fourth quarter worth about $29,000. SG Americas Securities LLC acquired a new position in shares of GoodRx in the first quarter worth approximately $29,000. Krilogy Financial LLC acquired a new position in shares of GoodRx in the first quarter worth approximately $33,000. Finally, Quarry LP bought a new stake in GoodRx in the third quarter valued at approximately $33,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.